Marker Therapeutics, Inc.

Category: Media Coverage

Note: When you click on media articles below a new page will open indicating that you are leaving the Marker Therapeutics Website and entering a third-party web site not affiliated with Marker Therapeutics Or any of its affiliates. No information contained in a linked site has been endorsed or approved by Marker Therapeutics And Marker Therapeutics Is not responsible for the content of such third-party website.

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic hematopoietic cell transplantation (alloHCT) and subsequently relapsed.

Read More

Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas

Researchers from Baylor College of Medicine and Texas Children’s Hospital are exploring “non-engineered” T-cell therapies that are easier to manufacture and able to target multiple antigens.

Read More

Houston: One of the Fastest-Growing Life Science Communities

A recent report by CBRE Research analyzing U.S. life science clusters found that Houston, Texas is the third-fastest growing life science market from 2014 to 2017.

Read More

Marker Therapeutics Rockets After CEO Says Phase 2 Leukemia Trial with T-cell Therapy in Works

With the help of Marker’s technology, a population of T-cells attacks multiple cancer targets and works to activate a patient’s immune system to trigger anti-tumor activity.

Read More

Marker Therapeutics: Phenomenal Data In Lymphoma And Other Indications, Yet Little Recognition From The Street

DLBCL data was particularly impressive. Patients who were third and fourth line refractory and relapsed post-transplant are experiencing durable and long responses with some now five years in remission.

Read More

Cancer-Focused Marker Therapeutics Shares Rise After Update on Clinical Trial Pipeline

The Houston, Texas-based immuno-oncology group gave an update on five clinical trials.

Read More

Marker Therapeutics Exits ASH An Optimist. Should That Be Enough For You?

Marker Therapeutics has emerged out of a merger with Tapimmune to push forward new cell-based cancer vaccines.

Read More

DoD Awards $11M for Phase 2 Trial of TPIV110 Breast Cancer Therapy

The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $11 million to conduct a Phase 2 trial investigating the TPIV110 vaccine, in combination with Herceptin (trastuzumab), as a therapy for women with HER2-positive breast cancer.

Read More

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 18th begins trading under the ticker (NASDAQ: MRKR), retiring TapImmune’s ticker (TPIV).

Read More

Mayo Clinic Lands $11 Million Grant to Study Breast Cancer Immunotherapy

The Department of Defense awarded more than $11 million for this Jacksonville study.

Read More